Mennen Medical Ventures is RCG’s new venture capital fund established to invest in medical-device start-ups so as to impact their development with the vast knowledge accrued in and derived from the medical devices division. Mennen Medical’s expertise will prove invaluable in such areas as R&D, production, regulation clearances, among others.
Mennen Medical Ventures’ first investment was Cardioscale. It is currently in the negotiation process with other medical-device start-ups.


CardioScale Ltd.

CardioScale is an Israeli medical start-up company. Founded in 2012, CardioScale developed and patented a new technology for the Cardio-Vascular Reserve Index (CVRI®) which evaluates heart failure severity and is used for early detection of cardiovascular deterioration and shock. CVRI-based devices evaluate, monitor and provide numeric results in seconds to improve quick decision making and disease management. Based on the CVRI® technology, CardioScale is currently developing innovative medical devices that will enable the assessment of a patient's hemodynamic status without taking invasive measures. The company, led by CEO Maoz Ben Ari, has successfully completed clinical trials in major hospitals and within the Israeli Defense Forces.

Learn more about CardioScale Ltd.